|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Amicus Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Amicus Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
11-1-2021 Insider Buy |
Burke W. Whitman Director |
$10.49
CAGR »
|
$15,735.00 1,500 shares |
10-1-2021 Insider Buy |
Burke W. Whitman Director |
$9.56
CAGR »
|
$14,346.00 1,500 shares |
9-1-2021 Insider Buy |
Burke W. Whitman Director |
$11.41
CAGR »
|
$17,115.00 1,500 shares |
8-2-2021 Insider Buy |
Burke W. Whitman Director |
$9.28
CAGR »
|
$13,920.00 1,500 shares |
7-1-2021 Insider Buy |
Burke W. Whitman Director |
$9.60
CAGR »
|
$14,400.00 1,500 shares |
6-1-2021 Insider Buy |
Burke W. Whitman Director |
$9.24
CAGR »
|
$13,861.20 1,500 shares |
5-25-2021 Insider Buy |
Lynn Dorsey Bleil Director |
$8.74
CAGR »
|
$250,007.70 28,605 shares |
5-3-2021 Insider Buy |
Burke W. Whitman Director |
$10.21
CAGR »
|
$15,315.00 1,500 shares |
4-1-2021 Insider Buy |
Burke W. Whitman Director |
$10.00
CAGR »
|
$15,000.00 1,500 shares |
3-1-2021 Insider Buy |
Burke W. Whitman Director |
$12.40
CAGR »
|
$18,600.00 1,500 shares |
2-1-2021 Insider Buy |
Burke W. Whitman Director |
$19.09
CAGR »
|
$28,636.80 1,500 shares |
1-4-2021 Insider Buy |
Burke W. Whitman Director |
$23.17
CAGR »
|
$34,755.00 1,500 shares |
12-1-2020 Insider Buy |
Burke W. Whitman Director |
$23.50
CAGR »
|
$35,250.00 1,500 shares |
11-2-2020 Insider Buy |
Burke W. Whitman Director |
$18.01
CAGR »
|
$27,015.00 1,500 shares |
10-1-2020 Insider Buy |
Burke W. Whitman Director |
$14.28
CAGR »
|
$21,412.95 1,500 shares |
9-1-2020 Insider Buy |
Burke W. Whitman Director |
$14.62
CAGR »
|
$21,930.00 1,500 shares |
8-3-2020 Insider Buy |
Burke W. Whitman Director |
$14.53
CAGR »
|
$21,795.00 1,500 shares |
7-1-2020 Insider Buy |
Burke W. Whitman Director |
$15.20
CAGR »
|
$22,800.00 1,500 shares |
10-3-2018 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$12.59
CAGR »
|
$629,700.00 50,000 shares |
9-21-2018 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$12.53
CAGR »
|
$626,500.00 50,000 shares |
9-13-2018 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$11.74
CAGR »
|
$1,174,000.00 100,000 shares |
9-12-2018 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$12.00
CAGR »
|
$6,001,500.00 500,000 shares |
3-5-2018 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$13.56
CAGR »
|
$4,553,814.12 335,827 shares |
3-2-2018 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$13.89
CAGR »
|
$1,389,500.00 100,000 shares |
3-1-2018 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$13.69
CAGR »
|
$1,369,000.00 100,000 shares |
7-13-2017 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$12.25
CAGR »
|
$18,375,000.00 1,500,000 shares |
12-30-2016 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$4.96
CAGR »
|
$470,054.75 94,750 shares |
12-29-2016 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$4.87
CAGR »
|
$692,622.50 142,125 shares |
12-23-2016 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$4.81
CAGR »
|
$410,049.58 85,275 shares |
12-22-2016 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$4.51
CAGR »
|
$854,834.50 189,500 shares |
6-3-2016 Insider Buy |
Redmile Group, LLC >10% Owner |
$7.20
CAGR »
|
$477,360.00 66,300 shares |
10-7-2015 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$6.27
CAGR »
|
$313,500.00 50,000 shares |
10-6-2015 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$6.71
CAGR »
|
$5,031,500.00 750,000 shares |
11-25-2014 Insider Buy |
Enrique Dilone VP, Technical Operations |
$8.00
CAGR »
|
$56,000.00 7,000 shares |
11-25-2014 Insider Buy |
Kenneth Peist VP, Legal & IP |
$8.00
CAGR »
|
$36,000.00 4,500 shares |
11-25-2014 Insider Buy |
Daphne Quimi VP Finance and Controller |
$8.00
CAGR »
|
$28,000.00 3,500 shares |
11-25-2014 Insider Buy |
Ken Valenzano VP, Pharmacology & Biology |
$8.00
CAGR »
|
$200,000.00 25,000 shares |
11-19-2014 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$6.50
CAGR »
|
$13,650,000.00 2,100,000 shares |
10-3-2014 Insider Buy |
Kenneth Peist VP, Legal & IP |
$7.00
CAGR »
|
$96,971.00 13,853 shares |
10-3-2014 Insider Buy |
Daphne Quimi VP Finance and Controller |
$7.00
CAGR »
|
$47,684.00 6,812 shares |
10-3-2014 Insider Buy |
Julie Yu VP Clinical Ops & Data Mgmt |
$7.00
CAGR »
|
$22,400.00 3,200 shares |
10-3-2014 Insider Buy |
Daphne Quimi VP Finance and Controller |
$7.00
CAGR »
|
$47,684.00 6,812 shares |
10-3-2014 Insider Buy |
Julie Yu VP Clinical Ops & Data Mgmt |
$7.00
CAGR »
|
$22,400.00 3,200 shares |
10-2-2014 Insider Buy |
Julie Yu VP Clinical Ops & Data Mgmt |
$5.99
CAGR »
|
$28,514.02 4,759 shares |
10-2-2014 Insider Buy |
Jeff Castelli VP, Program Management |
$6.01
CAGR »
|
$61,303.12 10,208 shares |
9-29-2014 Insider Buy |
Daphne Quimi VP Finance and Controller |
$6.10
CAGR »
|
$65,465.29 10,738 shares |
9-29-2014 Insider Buy |
William D. Baird III Chief Financial Officer |
$6.09
CAGR »
|
$154,111.09 25,311 shares |
9-29-2014 Insider Buy |
Kenneth Peist VP, Legal & IP |
$6.09
CAGR »
|
$171,803.64 28,208 shares |
8-27-2014 Insider Buy |
Jayne Gershkowitz VP, Patient Advocacy |
$7.00
CAGR »
|
$35,000.00 5,000 shares |
8-27-2014 Insider Buy |
Glenn Sblendorio Director |
$6.50
CAGR »
|
$65,000.00 10,000 shares |
8-25-2014 Insider Buy |
Enrique Dilone VP, Technical Operations |
$6.00
CAGR »
|
$42,000.00 7,000 shares |
8-25-2014 Insider Buy |
Jayne Gershkowitz VP, Patient Advocacy |
$6.00
CAGR »
|
$30,000.00 5,000 shares |
8-25-2014 Insider Buy |
Ken Valenzano VP, Pharmacology & Biology |
$6.00
CAGR »
|
$74,700.00 12,450 shares |
8-20-2014 Insider Buy |
Enrique Dilone VP, Technical Operations |
$5.40
CAGR »
|
$69,174.00 12,810 shares |
8-20-2014 Insider Buy |
Jayne Gershkowitz VP, Patient Advocacy |
$5.40
CAGR »
|
$32,832.00 6,080 shares |
8-20-2014 Insider Buy |
Ken Valenzano VP, Pharmacology & Biology |
$5.40
CAGR »
|
$37,800.00 7,000 shares |
6-30-2014 Insider Buy |
PERCEPTIVE ADVISORS LLC >10% Owner |
$3.50
CAGR »
|
$14,000,000.00 4,000,000 shares |
11-20-2013 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$2.00
CAGR »
|
$3,000,000.00 1,500,000 shares |
3-15-2013 Insider Buy |
Sol J. Barer Director |
$3.40
CAGR »
|
$85,000.00 25,000 shares |
11-13-2012 Insider Buy |
Joan Winterbottom SVP, Human Resources |
$4.54
CAGR »
|
$7,559.10 1,665 shares |
7-17-2012 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$6.30
CAGR »
|
$18,582,360.30 2,949,581 shares |
3-7-2012 Insider Buy |
M. James Barrett Director and >10% Owner |
$5.70
CAGR »
|
$5,273,377.80 925,154 shares |
3-7-2012 Insider Buy |
Mark W. Perry >10% Owner |
$5.70
CAGR »
|
$6,498,000.00 1,140,000 shares |
3-7-2012 Insider Buy |
Charles W. Newhall III >10% Owner |
$5.70
CAGR »
|
$6,498,000.00 1,140,000 shares |
3-7-2012 Insider Buy |
C. Richard Kramlich >10% Owner |
$5.70
CAGR »
|
$6,498,000.00 1,140,000 shares |
3-7-2012 Insider Buy |
Peter J. Barris >10% Owner |
$5.70
CAGR »
|
$6,498,000.00 1,140,000 shares |
3-7-2012 Insider Buy |
Enterprise Associates 11 LP New >10% Owner |
$5.70
CAGR »
|
$5,273,377.80 925,154 shares |
Also See: Institutional Holders of FOLD
Also See: SEC filings
Below we present the annualized performance delivered by Amicus Therapeutics stock since 11-1-2021 (the date of the most recent
insider purchase). The performance of the investment from the time Amicus Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about FOLD being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/02/2021 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$11.91 |
|
End price/share: |
$10.61 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-10.92% |
|
Average Annual Total Return: |
-4.58% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,909.46 |
|
Years: |
2.46 |
|
Amicus Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Amicus Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding FOLD
|
|